Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Value-Based Cancer Care

- PMLiVE

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Part of R&D and commercial collaboration with MSD

- PMLiVE

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Acquires its portfolio of NLRP3 targeting drugs

Bristol Myers Squibb logo

BMS closes on Celgene merger after rebel investors bow out

News on Revlimid patent also positive

- PMLiVE

Bluebird gets European recommendation for gene therapy Zynteglo

Company advanced in novel reimbursement plan

- PMLiVE

Call for temporary medicines export ban if no-deal Brexit strikes

NHS could struggle to source medicines

AstraZeneca AZ

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

Filing due later this year

- PMLiVE

Gilead and Galapagos close in on filing for Xeljanz rival

Belgian biotech gearing up for first approval

Daiichi Sankyo logo

Daiichi Sankyo starts mirogabalin trial in spinal injury pain

Trial will enrol 274 subjects with post-spinal cord injury neuropathic pain

- PMLiVE

UK business: Brexit deadlock causing “frustration and anger”

Pharma must still plan for no-deal, only slightly later

- PMLiVE

NICE recommends MSD’s diabetes drug Steglatro

MSD offering lowest price to win share of SGLT-2 inhibitor market

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

FDA approves Novartis’ next-gen MS drug Mayzent

Drug reduces risk of disease progression

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links